Ron Chen is a Licensed Certified Public Accountant (CPA) in Massachusetts with over 17 years of experience in accounting and finance. He currently serves as the Vice President of Finance and Corporate Controller at Aileron, a role he assumed in December 2023.

Prior to joining Aileron, Ron held the position of Corporate Controller at Reata Pharmaceuticals, overseeing financial operations. During his tenure, Reata successfully initiated commercialization following FDA approval of its first product and it was acquired by Biogen in July 2023.

From February 2020 to April 2022, Ron served as Assistant Controller at Pear Therapeutics, where he contributed to the company’s successful public listing through a special purpose acquisition company (SPAC) deal in 2021.

From March 2017 to February 2020, Ron served as the technical accounting and SEC reporting lead at Bioverativ, and later at Sanofi following Bioverativ’s acquisition in January 2018. At Sanofi, a global leader in immunology, Ron played a key role in managing financial operations and reporting for a major pharmaceutical entity.

Earlier in his career, Ron worked as an auditor at Ernst & Young LLP, one of the world’s largest professional services firms, where he honed his expertise in accounting and financial auditing Ron holds a Bachelor of Science degree in Finance from Nanjing University in China and a Master of Science degree in Accounting from Boston College.